COVID-19–associated cognitive decline in type 2 diabetes: Comparative cohort outcomes and therapeutic implications

نویسندگان
doi
10.48309/jmpcr.2026.560845.1902
چکیده

This longitudinal cohort study investigated the impact of COVID-19 on cognitive function in patients with pre-existing type 2 diabetes mellitus (T2DM), focusing on post-infection outcomes and therapeutic responses. A total of 1,356 T2DM individuals with confirmed COVID-19 were evaluated using the mini-mental state examination (MMSE), along with psychosocial assessments (PHQ-9 and GAD-7) and biomarkers of inflammation. The results revealed a significant post-COVID cognitive decline, particularly among those with moderate to severe infections, with a marked association between MMSE scores and systemic inflammation, depression, and anxiety. Multivariate regression identified COVID severity, inflammatory burden, and psychological distress as key predictors of cognitive impairment. Therapeutic interventions, pharmacological interventions (GLP-1 and SGLT2 inhibitors), and cognitive behavioral therapy (CBT) as well as mindfulness-based rehabilitation, demonstrated statistically significant cognitive and emotional improvements over 12 months. These findings highlight the critical need for integrated post-COVID care strategies targeting neurocognitive and psychosocial health in T2DM patients to mitigate long-term cognitive sequelae.